Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Polydex reports commencement of Ushercell Phase I trial
This study will recruit 60 women over a six-month period at two sites in the US. Assigned products to be evaluated in this trial include Ushercell, nonoxynol-9 and
This study will recruit 60 women over a six-month period at two sites in the US. Assigned products to be evaluated in this trial include Ushercell, nonoxynol-9 and
The Phase I trial will evaluate the safety and maximum tolerable dose of sublingual-oral immunotherapy in patients with confirmed Timothy grass pollen allergy and history of at least
The Phase II trial evaluated the neuroprotective capacity of two combinations, AL-08 and minocycline versus AL-08 with celecoxib, using group sequential design and a natural history control group
The study will use Biocept’s proprietary CEE (Cell Enrichment and Extraction) technology, designed to capture rare cells from a larger heterogeneous cell population. The focus of this study
The company has been marketing the CellerateRx brand of products within the US to the human health care market. CellerateRx is available in two forms, a powder and
Combined with Apria’s existing infusion patient base, the new infusion division, which will remain headquartered in Denver, Colorado, is expected to care for more than 100,000 patients annually
This round, co-led by Medtronic and Johnson and Johnson Development Corporation, also includes Oakwood Medical, Palisades Capital and Accelerated Technology Partners. Existing investors Forbion, Giza, Oxford Biosciences and
Through its mobile imaging operations, Digirad will bring state-of-the-art equipment and qualified, trained personnel into physicians’s offices to perform the imaging. The patients’s images will be interpreted by
The research involves fibroblast growth factor-2 (FGF-2), a naturally occurring protein that has been studied extensively for its neuroprotective properties. After being treated with FGF-2, mice with Huntington’s
The potential acquisition would combine Progenitor Cell Therapy’s (PCT) cGMP-quality cell processing and contract manufacturing business with the cell-based research and development programs of StemCells. PCT has agreed